Psilocybin's FDA Clock Just Started Ticking — the DEA's Hasn't

Five VA hospitals — in Birmingham, Tuscaloosa, Portland, Philadelphia, and the Puget Sound area outside Seattle — started enrolling veterans this week in a trial called PIVOT, testing two psilocybin dosage levels against treatment-resistant depression, including in veterans who also carry PTSD. VA Secretary Doug Collins put it plainly: “Far too many Veterans are living with mental health conditions that don’t respond to available treatments.” That trial alone would be news. It landed the same week Compass Pathways confirmed both of its Phase 3 psilocybin trials hit their marks, and the FDA scheduled a public hearing on where psychedelic medicine goes next. Three separate institutions, eight days, one drug class.

THE TAKE: FDA approval of psilocybin therapy is now the least interesting open question in this story — DEA rescheduling is the one nobody’s forcing a timeline on.

Start with why the FDA path looks close. Compass reported that 39% of participants in one trial reached meaningful improvement by week six, with effects holding at six months — durability being the exact number every earlier psychedelic trial has struggled to prove. The company is filing a rolling NDA, submitting its New Drug Application in sections as data clears rather than holding everything for one submission, with the final piece due in the fourth quarter. It also holds a Commissioner’s National Priority Voucher, a fast-track credential that can shrink FDA’s review window from a standard 10-to-12 months down to as little as one or two. For a field that has measured itself in decades since the 1970s scheduling freeze, a two-month clock is a different universe.

The FDA’s own guidance, finalized in the Federal Register in July, targets the flaw that sank the last major psychedelic application: functional unblinding, the problem where a participant and their therapist can usually tell within the first hour who received the real drug and who got placebo, because a hallucinogen doesn’t disguise itself as a sugar pill. That ambiguity is what undid Lykos Therapeutics’ MDMA submission, and the FDA’s September 14 hearing, open for speaker requests through August 21, is the agency laying out its trial-design thinking in public before the next application arrives.

None of that moves the DEA. Psilocybin still sits in Schedule I, the federal category for drugs the government says have no accepted medical use — and no doctor can legally write that prescription while it stays there, regardless of what the FDA decides. Compass’s own commercial launch, projected for the first half of 2027, is contingent on both agencies acting, not one. Then there’s coverage: roughly 4 million Americans carry treatment-resistant depression, current antidepressants hold under 3% of that market, and no insurer has said what a psilocybin session — hours of supervised in-office time, not a bottle from a pharmacy — will cost the person taking it. For more on where this class of substances stands clinically, see our psychedelics and empathogens coverage.

A veteran in Birmingham can raise a hand for a trial this month. A prescription, a covered appointment, and an open clinic door are still three separate approvals away, sitting on three agencies’ desks that are not reading from the same calendar.